Retatrutide vs Semaglutide vs Tirzepatide: How the Incretin Research Peptides Differ

The defining difference between these three incretin research peptides is how many hormone receptors each one targets. Semaglutide is a single agonist that activates only the GLP-1 receptor. Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. Retatrutide is a triple agonist that activates the GIP, GLP-1, and glucagon receptors. That stepwise increase in receptor coverage — one, then two, then three targets — is the cleanest way to understand how the molecules relate to one another in the published literature.

Research-use-only (RUO) note: the compounds discussed here are sold strictly as research materials for laboratory use. They are not the branded medicines named below, are not drugs, and are not intended for human or veterinary use, diagnosis, or treatment. All effects described are findings reported in clinical or preclinical studies, not outcomes you should expect.

Quick comparison

Compound	Receptor targets	Approval status
Semaglutide	GLP-1 (single agonist)	Approved medicine (e.g. Ozempic, Wegovy)
Tirzepatide	GIP + GLP-1 (dual agonist)	Approved medicine (e.g. Mounjaro, Zepbound)
Retatrutide	GIP + GLP-1 + glucagon (triple agonist)	Investigational — not approved; in clinical trials

The research materials offered here are RUO chemicals supplied for laboratory study and are distinct from any approved product.

Semaglutide (single agonist)

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist — it engages a single incretin receptor. In its approved medicinal forms it is a long-acting compound suited to once-weekly administration. In the STEP 1 clinical trial reported in the literature, researchers studied semaglutide in adults with overweight or obesity over 68 weeks [2]. For more, see our full article.

Tirzepatide (dual agonist)

Tirzepatide adds a second target. It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The idea studied in the literature is that activating GIP alongside GLP-1 may act in combination rather than relying on GLP-1 alone. The SURMOUNT-1 trial evaluated tirzepatide over 72 weeks in adults with obesity [3]. Learn more in our full article, and compare the two directly in Semaglutide vs Tirzepatide.

Retatrutide (triple agonist)

Retatrutide extends the concept to a third receptor. It is a triple agonist of the GIP, GLP-1, and glucagon receptors — the glucagon component is what distinguishes it from tirzepatide. Because it is investigational and not approved, it exists today only as a research compound. A phase 2 trial published in the New England Journal of Medicine studied retatrutide in adults with obesity over 48 weeks [1]. See our full article for more.

Key differences studied in research

• Receptor count. The core distinction is mechanistic: one receptor (semaglutide), two receptors (tirzepatide), three receptors (retatrutide). Each step adds a hormone pathway to the molecule’s activity.
• The added pathways. Tirzepatide layers GIP-receptor activity onto GLP-1. Retatrutide layers both GIP and glucagon-receptor activity onto GLP-1 — the glucagon component is unique among the three.
• Trial findings (attributed to the literature). The published phase 2 and phase 3 trials cited below reported reductions in body weight versus placebo across all three compounds, with greater reductions generally reported for the multi-receptor agonists [1][2][3]. These are reported study outcomes, not claims about what any research material will do.
• Reported adverse events. Across the trials, the most commonly reported adverse events were gastrointestinal (such as nausea, vomiting, and diarrhea), described in the literature as consistent with the incretin-agonist class [1].

Research status and safety

Approval status differs sharply across the three. Semaglutide and tirzepatide are active ingredients in approved prescription medicines sold under brand names. Retatrutide is investigational and has not been approved by the FDA or any comparable regulator. None of this changes what is offered here: the items on this site are research-use-only chemicals intended exclusively for in-vitro and laboratory research by qualified personnel. They are not medicines, are not bioequivalent to any approved product, and must never be administered to humans or animals.

Handling

Research peptides are typically supplied as a lyophilized (freeze-dried) powder that must be prepared correctly for laboratory work. See our reconstitution guide, and browse the full GLP research peptides category.

FAQ

What is the single biggest difference between the three? Receptor count. Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GIP and GLP-1), and retatrutide targets three (GIP, GLP-1, and glucagon). The glucagon receptor is the target unique to retatrutide.

Are these the same as the brand-name products? No. Semaglutide and tirzepatide are active ingredients in approved medicines, and retatrutide is an investigational compound. The materials sold here are research-use-only chemicals, are not those medicines, and are not for human use.

Which one is “best”? That question does not apply to research materials. We make no efficacy, weight-loss, or appetite claims. The trials cited below report their own outcomes; this article only summarizes how the molecules differ by mechanism.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.

For research use only. Not for human or veterinary use. The research materials are not the approved/investigational medicines. Statements have not been evaluated by the FDA.